"The Effectivenes of Medicinal Cannabis in Adults with Non-Cancer Diagnoses"

This research conducted through a retrospective medical record review aimed to describe the characteristics and effectiveness of medicinal cannabis use in adults with non-cancer diagnoses in Australia. 

People with chronic conditions may benefit from using medicinal cannabis for treating chronic pain, multiple sclerosis, Parkinson’s and other conditions. 

The study reviewed 157 medical records, with the majority of patients were predominantly female (63.7%), aged 63.0 years, and from the Greater Sydney region (86.6%). Most patients were born in Australia (66.9%) , with 17.8% stating previous cannabis use and having neurological (58.0%) or musculoskeletal (24.8%) conditions.

The findings showed that 53.5% of patients perceived medicinal cannabis to be beneficial. Significant changes over time were observed in various symptom assessments, including pain, bowel problems, fatigue, difficulty sleeping, mood, quality of life (QoL), breathing problems, and appetite.

"Neuroprotective Effects Of Cannabis" by Sensi Seed

Following on from our recent article on the relationship between cannabis use and stroke, we now investigate the role of cannabinoids in mitigating brain damage caused by traumatic brain injury and ischemic stroke. There is mounting evidence to suggest that their various properties have great therapeutic potential.

-Antioxidative & anti-inflammatory properties

In recent years the evidence for the antioxidative and anti-inflammatory properties of various cannabinoids has become well-established, and our understanding of the role they play in modulating neurotransmission too has grown. Thus, serious consideration is now being given to their potential as neuroprotective agents. Cannabinoids have been shown to prevent neuronal death in acute neuronal injury, including Ischemic Stroke (IS) and Traumatic Brain Injury (TBI), as well as provide symptomatic relief in Multiple Sclerosis (MS), Huntington’s disease, and other chronic neurodegenerative diseases.

"Prescription of a THC/CBD-Based Medication to Patients with Dementia: A Pilot Study in Geneva"

Dementia is characterized by a deterioration in memory, thinking, behavior, and autonomy in daily life activities. 

According to the World Health Organization, there were around 50 million persons worldwide suffering from dementia and this number is increasing with the global aging of the population in most countries. 

Currently, the options for treating BPSD (Behavioral and Psychological Symptoms of Dementia) include pharmacological and nonpharmacological therapies. Psychotropic medications are often used to reduce the frequency and severity of BPSD, but in the majority of patients, they provide only modest symptom control and important side effects.

The interest of cannabinoids in Alzheimer disease and other forms of dementia has increased first as neuroprotective drugs in animal studies. Indeed, some studies suggest a potential beneficial effect of CB1 and CB2 receptor agonists on reducing harmful β-amyloid peptide action and tau phosphorylation seen in Alzhei­mer disease as well as increasing intrinsic brain repair mechanisms.

"Can CBD help With Neuroinflammation"

Neuroinflammation is an inflammatory condition of the brain, in which glial cells,namely,astrocytes 
and microglia,the resident macrophages of the brain, are involved along with blood-borne cells. 

Although in the past glial activation in neuroinflammation has been considered detrimental to the brain in general, currently the reparative/ protective aspects are being recognized. 

Cannabinoids, whether plant derived or endogenous  affect different glial functions. 

Importantly, glial cells are endowed with several, if not all, of the elements of the endocannabinoid system, and therefore are sensitive to cannabinoids and at the same time are a source of endocannabinoids. 

There appears to be general agreement that cannabinoids reduce the synthesis, production, and release of cytotoxic molecules such as proinflammatory cytokines and nitric oxide. 

On the other hand, these agents modify microglial cell migration in such a way that the result is usually beneficial in resolving neuroinflammation or limiting ensuing neurodegeneration.